ProCE Banner Activity

MANIFEST: Pelabresib (CPI-0610) Monotherapy in Patients With Myelofibrosis

Slideset Download
Conference Coverage
In this open-label phase II trial, pelabresib was associated with clinical activity in patients with pretreated myelofibrosis who were refractory/resistant to, ineligible for, or intolerant to JAK inhibitors.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation